Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus

Area of Science:

• Biochemistry
• Genetics
• Obstetrics

Background:

• Gestational diabetes mellitus (GDM) poses significant risks to both mother and fetus.
• Serum microRNAs (miRNAs) are stable, abundant, and potentially disease-specific biomarkers.
• No prior studies have investigated the link between serum miRNAs and GDM.

Purpose of the Study:

• To investigate the association between serum miRNA expression and GDM.
• To identify potential serum miRNA biomarkers for GDM prediction.

Main Methods:

• Serum samples were collected at 16-19 gestational weeks.
• TaqMan Low Density Array and quantitative reverse transcription polymerase chain reaction were used for miRNA screening.
• External validation was performed on two independent sample sets.

Main Results:

• miR-132, miR-29a, and miR-222 expression levels were significantly decreased in GDM patients compared to controls.
• miR-29a and miR-222 were consistently validated in external sample sets.
• In vitro, miR-29a knockdown increased Insig1 and PCK2 expression in HepG2 cells.

Conclusions:

• Serum miRNAs are differentially expressed in GDM patients, suggesting their potential as predictive biomarkers.
• miR-29a, miR-222, and miR-132 show promise as non-invasive serum biomarkers for GDM.
• Further research is needed to optimize the clinical utility of these miRNA biomarkers.